These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26297262)

  • 1. Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia.
    Egan D; Radich J
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S109-13. PubMed ID: 26297262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular monitoring of response in patients with chronic myeloid leukemia.
    Kolibaba KS
    Manag Care; 2013 Jul; 22(7):40, 50-61. PubMed ID: 23936973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
    Kelani R; Monem F
    Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
    Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
    Geng SX; Weng JY; Huang X; Lu ZS; Wu P; Huang LS; Liu L; Du X
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):561-5. PubMed ID: 23906446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
    Lai Y; Qin Y; Huang X; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
    Luu MH; Press RD
    Expert Rev Mol Diagn; 2013 Sep; 13(7):749-62. PubMed ID: 24063401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
    Lau A; Seiter K
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.